About us Contacts Drug interactions: 390 212
Drug search by name

Lithium Controlled-Release and Extended-Release Tablets and Pexeva

Determining the interaction of Lithium Controlled-Release and Extended-Release Tablets and Pexeva and the possibility of their joint administration.

Check result:
Lithium Controlled-Release and Extended-Release Tablets <> Pexeva
Relevance: 05.06.2022 Reviewer: Shkutko P.M., M.D., in

In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.

Consumer:

Talk to your doctor before using lithium together with PARoxetine. Combining these medications can increase the risk of a rare but serious condition called the serotonin syndrome, which may include symptoms such as confusion, hallucination, seizure, extreme changes in blood pressure, increased heart rate, fever, excessive sweating, shivering or shaking, blurred vision, muscle spasm or stiffness, tremor, incoordination, stomach cramp, nausea, vomiting, and diarrhea. Severe cases may result in coma and even death. You should contact your doctor immediately if you experience these symptoms while taking the medications. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

Professional:

MONITOR CLOSELY: Lithium may enhance the pharmacologic effects of selective serotonin reuptake inhibitors (SSRIs) and potentiate the risk of serotonin syndrome, which is a rare but serious and potentially fatal condition thought to result from hyperstimulation of brainstem 5-HT1A and 2A receptors. The exact mechanism by which lithium increases serotonergic activity is unknown. The interaction has been reported with fluoxetine and fluvoxamine and the serotonin-norepinephrine reuptake inhibitor venlafaxine. Symptoms of the serotonin syndrome may include mental status changes such as irritability, altered consciousness, confusion, hallucinations, and coma; autonomic dysfunction such as tachycardia, hyperthermia, diaphoresis, shivering, blood pressure lability, and mydriasis; neuromuscular abnormalities such as hyperreflexia, myoclonus, tremor, rigidity, and ataxia; and gastrointestinal symptoms such as abdominal cramping, nausea, vomiting, and diarrhea. Conversely, SSRIs may elevate the plasma concentrations of lithium and increase the risk of lithium toxicity. The interaction has been associated with fluoxetine, while citalopram and paroxetine reportedly do not cause the interaction. Excessive somnolence has been reported with lithium and fluvoxamine.

MANAGEMENT: Caution is advised if lithium is prescribed in combination with SSRIs. Lithium levels should be assessed regularly and the dosage adjusted accordingly. Patients should be closely monitored for symptoms of the serotonin syndrome during treatment. Particular caution is advised when increasing the dosages of these agents. The potential risk for serotonin syndrome should be considered even when administering serotonergic agents sequentially, as some agents may demonstrate a prolonged elimination half-life. For example, a 5-week washout period is generally recommended following use of fluoxetine before administering another serotonergic agent. If serotonin syndrome develops or is suspected during the course of therapy, all serotonergic agents should be discontinued immediately and supportive care rendered as necessary. Moderately ill patients may also benefit from the administration of a serotonin antagonist (e.g., cyproheptadine, chlorpromazine). Severe cases should be managed under consultation with a toxicologist and may require sedation, neuromuscular paralysis, intubation, and mechanical ventilation in addition to the other measures.

References
  • Hadley A, Cason MP "Mania resulting from lithium-fluoxetine combination." Am J Psychiatry 146 (1989): 1637-8
  • Sobanski T, Bagli M, Laux G, Rao ML "Serotonin syndrome after lithium add-on medication to paroxetine." Pharmacopsychiatry 30 (1997): 106-7
  • "Product Information. Zoloft (sertraline)." Roerig Division, New York, NY.
  • "Product Information. Brintellix (vortioxetine)." Takeda Pharmaceuticals America, Lincolnshire, IL.
  • Muly EC, McDonald W, Steffens D, Book S "Serotonin syndrome produced by a combination of fluoxetine and lithium." Am J Psychiatry 150 (1993): 1565
  • Corkeron MA "Serotonin syndrome - a potentially fatal complication of antidepressant therapy." Med J Aust 163 (1995): 481-2
  • Sternbach H "The serotonin syndrome." Am J Psychiatry 148 (1991): 705-13
  • "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals, St. Louis, MO.
  • Noveske FG, Hahn KR, Flynn RJ "Possible toxicity of combined fluoxetine and lithium." Am J Psychiatry 146 (1989): 1515
  • Nierenberg DW, Semprebon M "The central nervous system serotonin syndrome." Clin Pharmacol Ther 53 (1993): 84-8
  • Martin TG "Serotonin syndrome." Ann Emerg Med 28 (1996): 520-6
  • "Product Information. Paxil (paroxetine)." GlaxoSmithKline, Research Triangle Park, NC.
  • Mills KC "Serotonin syndrome: A clinical update." Crit Care Clin 13 (1997): 763
  • Bodner RA, Lynch T, Lewis L, Kahn D "Serotonin syndrome." Neurology 45 (1995): 219-23
  • "Product Information. Prozac (fluoxetine)." Dista Products Company, Indianapolis, IN.
  • "Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc, Marietta, GA.
  • "Product Information. Celexa (citalopram)." Forest Pharmaceuticals, St. Louis, MO.
  • Fagiolini A, Buysse DJ, Frank E, Houck PR, Luther JF, Kupfer DJ "Tolerability of combined treatment with lithium and paroxetine in patients with bipolar disorder and depression." J Clin Psychopharmacol 21 (2001): 474-8
  • Darcy PF, Griffin JP "Interactions with drugs used in the treatment of depressive illness." Adverse Drug React Toxicol Rev 14 (1995): 211-31
  • Salama AA, Shafey M "A case of severe lithium toxicity induced by combined fluoxetine and lithium carbonate." Am J Psychiatry 146 (1989): 278
Lithium Controlled-Release and Extended-Release Tablets

Generic Name: lithium

Brand name: Lithobid, Eskalith, Lithonate, Lithotabs, Eskalith-CR

Synonyms: Lithium

Pexeva

Generic Name: paroxetine

Brand name: Brisdelle, Paxil, Paxil CR, Pexeva

Synonyms: n.a.

In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.